List of Excipients in Branded Drug COLESEVELAM HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cosette Pharmaceuticals Inc	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	0713-0936	CELLULOSE, MICROCRYSTALLINE
Cosette Pharmaceuticals Inc	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	0713-0936	HYPROMELLOSE
Cosette Pharmaceuticals Inc	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	0713-0936	MAGNESIUM STEARATE
Cosette Pharmaceuticals Inc	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	0713-0936	SILICON DIOXIDE
A-S Medication Solutions	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	50090-6994	CELLULOSE, MICROCRYSTALLINE
A-S Medication Solutions	COLESEVELAM HYDROCHLORIDE	colesevelam hydrochloride	50090-6994	HYPROMELLOSE

Generic Drugs Containing COLESEVELAM HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	colesevelam hydrochloride	0115-1320	CELLULOSE, MICROCRYSTALLINE
Amneal Pharmaceuticals of New York LLC	colesevelam hydrochloride	0115-1320	COPOVIDONE K25-31
Amneal Pharmaceuticals of New York LLC	colesevelam hydrochloride	0115-1320	HYPROMELLOSE 2910
Amneal Pharmaceuticals of New York LLC	colesevelam hydrochloride	0115-1320	MAGNESIUM STEARATE
Amneal Pharmaceuticals of New York LLC	colesevelam hydrochloride	0115-1320	POLYETHYLENE GLYCOL 6000
Amneal Pharmaceuticals of New York LLC	colesevelam hydrochloride	0115-1320	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in COLESEVELAM HYDROCHLORIDE?

# Of NDCs	Excipient
11	AMMONIA
3	ASPARTAME
2	BUTYL ALCOHOL
21	CELLULOSE, MICROCRYSTALLINE
4	CI 77499
3	CITRIC ACID MONOHYDRATE

Excipient Strategy and Commercial Opportunities for Colesevelam Hydrochloride

Last updated: February 28, 2026

What role do excipients play in colesevelam hydrochloride formulations?

Excipients in colesevelam hydrochloride formulations primarily serve to improve drug solubility, stability, and bioavailability. As a non-absorbed resin, colesevelam binds bile acids in the gastrointestinal tract, lowering LDL cholesterol. The excipient matrix supports its functionality and manufacturability.

Common excipients include binders, pH adjusters, and disintegrants. Microcrystalline cellulose and magnesium stearate are frequently incorporated for tablet stability and compressibility. The choice of excipients impacts drug delivery efficiency, patient tolerability, and shelf life.

How does excipient selection influence manufacturing and formulation?

Excipients directly affect:

• Manufacturing process: Compatibility with high-shear mixing, compression, and coating processes.
• Stability: Prevention of degradation or moisture absorption.
• Bioavailability: Facilitating release and ensuring consistent dosing.
• Patient compliance: Taste masking, disintegration profile, and tablet size.

Selecting excipients that optimize these factors can reduce production costs and improve product stability, which is crucial given colesevelam's non-absorptive, resin-based nature.

What are key commercial considerations for excipient strategies?

Commercial opportunities hinge on innovation in excipient use to:

• Enable new formulations: Oral granules, suspensions, or formulations with improved tolerability.
• Enhance bioavailability: Proprietary excipients or delivery systems that improve drug release.
• Reduce costs: Use of cost-efficient excipients without compromising quality.
• Support Expanded Indications: Formulations suitable for pediatric or geriatric populations, requiring excipients that ensure safety and compliance.

Companies investing in excipient R&D can differentiate through patent protection, superior product profiles, and cost advantages.

What are emerging trends and opportunities?

Emerging trends include:

• Use of functional excipients: Excipients with dual roles, such as carriers that enhance binding and stability.
• Nanotechnology: Incorporation of nanocarriers to improve solubility and targeted delivery.
• Modified release systems: Controlled-release matrices to extend dosing intervals, improving compliance.

These innovations provide opportunities for pharmaceutical firms to develop differentiated products, potentially commanding premium pricing and patent barriers.

How do regulatory considerations influence excipient strategies?

Regulatory agencies require excipient transparency and safety documentation. Strategies must include:

• GRAS (Generally Recognized As Safe) status for excipients.
• Documentation of compatibility with colesevelam hydrochloride.
• Clear labeling and adherence to USP, Ph. Eur., or other pharmacopoeial standards.

Regulatory pathways influence product development timelines and market access. Patent protections on innovative excipient combinations can extend market exclusivity.

What is the market landscape and competitive positioning?

The global hypercholesterolemia treatment market is projected to reach USD 20 billion by 2027 [1]. Colesevelam hydrochloride's market share is growing due to its favorable safety profile and efficacy.

Major competitors include generic manufacturers and newer lipid-lowering agents like PCSK9 inhibitors. Excipient innovations can provide competitive edges through improved formulations that address patient adherence issues or reduce side effects.

Companies that develop proprietary excipient systems or novel delivery methods can establish barriers to entry and command higher margins.

Key commercial opportunities:

• Formulation innovation: Developing patient-friendly, stable, and cost-effective products.
• Patent protection: Securing intellectual property on excipient combinations and delivery systems.
• Market expansion: Adapting formulations for pediatric or special-needs patients.
• Regulatory advantages: Utilizing excipients with established safety profiles for faster approval.

Key Takeaways

• Excipient selection significantly impacts colesevelam hydrochloride's stability, bioavailability, and patient compliance.
• Innovation in excipient technology can lead to differentiated products, new patent opportunities, and cost efficiencies.
• Regulatory compliance remains a critical factor in excipient strategy development.
• Market growth driven by hypercholesterolemia prevalence and expanding indications presents commercial opportunities.
• Proprietary delivery systems and functional excipients can provide competitive advantages.

FAQs

1. Can new excipient technologies improve colesevelam hydrochloride efficacy?
Yes, novel excipients or delivery systems can enhance drug release, stability, or tolerability, potentially improving efficacy and adherence.

2. How important is regulatory approval for excipients used in colesevelam formulations?
Regulatory approval ensures safety and quality, facilitating market access and reducing delays.

3. Are there patent opportunities related to excipients for colesevelam?
Yes, proprietary combinations or delivery systems involving excipients can be patented, extending market exclusivity.

4. What regulatory hurdles exist for introducing new excipients?
New excipients require comprehensive safety data and regulatory submission, which can extend time to market.

5. How does excipient choice influence patient adherence?
Excipients impact tablet size, taste, disintegration, and side effect profile, which influence patient compliance.

---

References

[1] Markets and Markets. (2022). Hypercholesterolemia Treatment Market by Drug Class, Route of Administration, and Region.